Vascular Phenotyping: A New Paradigm in Drug Development

Vascular phenotyping has emerged as an important tool in advancing our understanding of cardiovascular and chronic diseases. By providing non-invasive, digital biomarkers of vascular function phenotyping enables an early identification of subclinical disease, and a more precise approach to risk stratification and therapeutic effectiveness.  Key modalities, including arterial stiffness indices, endothelial function assessments and advanced imaging techniques, offer insights from early vascular changes through the spectrum of vascular disease and cardiovascular events including myocardial infarction and stroke.

Incorporating vascular phenotyping into clinical trials enhances the mechanistic understanding of investigational therapies, facilitates personalized treatment approaches, and strengthens the predictive value of trial outcomes. It is particularly important in studies targeting cardiovascular, respiratory, renal, and metabolic diseases as well as in women’s health and in various ethnicities where vascular changes is both a mediator and a marker of disease progression.

As precision medicine continues to evolve, vascular phenotyping serves as an indispensable bridge between research and clinical application, ultimately improving patient care and therapeutic innovation.

Register for this webinar today to explore how vascular phenotyping can be included in the design of clinical trials, and how new digital health technologies that capture biomarkers of vascular disease can be used to determine the efficacy of emerging therapies.

Speaker

Dr. Sanjeev Bhavnani, MD FACC, Chief Clinical Officer, Cardiex

Dr. Sanjeev Bhavnani is a distinguished physician, digital health clinical trialist and policy strategist with over two decades of experience in advancing healthcare innovation through leadership roles across health systems, government and private sectors.

Specializing in the integration of digital health technologies (DHTs) and artificial intelligence/machine learning (AI/ML) into clinical practice, Dr. Bhavnani has successfully led multidisciplinary teams in the design, execution and management of high-impact clinical trials, resulting in multiple FDA approvals.

A passionate advocate for diversity, equity and inclusion (DE&I), Dr. Bhavnani is dedicated to pioneering inclusive healthcare solutions and shaping national policy to drive equitable access to cutting-edge medical innovations.

Message Presenter